Versant Capital Management’s Cytokinetics CYTK Stock Holding History

Versant Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.33K	Sell	86 -42	-33%	-$3.02K	﹤0.01%	2334
2026 Q1	$8.44K	Buy	128 +86	+205%	+$5.47K	﹤0.01%	2210
2025 Q4	$2.67K	Buy	+42	New	+$2.61K	﹤0.01%	2400
2025 Q1	–	Sell	-11	Closed	-$517	–	2546
2024 Q4	$517	Buy	+11	New	+$571	﹤0.01%	2269
2021 Q2	–	Sell	-419	Closed	-$10K	–	1471
2021 Q1	$10K	Sell	419 -205	-33%	-$4.38K	﹤0.01%	783
2020 Q4	$12K	Sell	624 -39	-6%	-$713	﹤0.01%	671
2020 Q3	$14K	Hold	663	–	–	0.01%	535
2020 Q2	$15K	Buy	663 +314	+90%	+$5.89K	0.01%	498
2020 Q1	$4K	Buy	349 +12	+4%	+$153	﹤0.01%	823
2019 Q4	$3K	Hold	337	–	–	﹤0.01%	1055
2019 Q3	$3K	Hold	337	–	–	﹤0.01%	1078
2019 Q2	$3K	Buy	337 +256	+316%	+$2.47K	﹤0.01%	1084
2019 Q1	$0	Hold	81	–	–	﹤0.01%	1588
2018 Q4	$0	Hold	81	–	–	﹤0.01%	1499
2018 Q3	$0	Buy	+81	New	+$650	﹤0.01%	1538
2018 Q2	–	Sell	-21	Closed	–	–	1529
2018 Q1	$0	Buy	+21	New	+$180	﹤0.01%	1512

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Versant Capital Management's CYTK Position: Q2 2026 in Review

Versant Capital Management reduced its Cytokinetics (CYTK) stake by 33% in Q2 2026, selling an estimated $3.02K and leaving 86 shares worth $7.33K. The position accounts for ﹤0.01% of the portfolio, ranked #2334.

Versant Capital Management first reported a position in CYTK in Q1 2018 and has held it in 16 quarters since. The position peaked at $15K in Q2 2020. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Versant Capital Management held 86 shares of Cytokinetics worth $7.33K as of Q2 2026.
Versant Capital Management sold 42 Cytokinetics shares in Q2 2026, an estimated $3.02K.
Cytokinetics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2334 holding.
Versant Capital Management first reported a position in Cytokinetics in Q1 2018 and has held it in 16 quarters since.
Versant Capital Management's Cytokinetics position peaked at $15K in Q2 2020.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.